Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
They l catch on when we're over £1 and happy to top up on the way up.
When people actually do some research here and recognize the potential v the current market cap v current shares available in issue.
Moving on thin air now
And yet , alas Bottomzup departs .
Well done all holders, faith in Biomerics seems to be bearing fruit .
It`s been quite a long road .
Best of Brown
Absolutely Liam
New Chapter
The long-running litigation dispute created a number of uncertainties for AorTech and its shareholders and at the time of announcing results for the year to 31 March 2017 the share price was implying that AorTech was likely to fail.
The recent trading results should indicate to shareholders that the business is on a more stable footing and the risk of failure diminished. The cash position improved during the six months to 30 September 2017 and at the end of November 2017 had further increased to $328,000. As a result of the conclusion of the litigation, AorTech will have certain costs to pay and make reimbursements to our insurance provider. However, we anticipate that the net cash position should improve further.
The Board has conducted a thorough review of the Company's IP and where it fits into the medical device market, leading to the conclusion that there are a number of opportunities available to grow AorTech's business. A detailed strategic plan to allow AorTech to commercialise its platform technology is currently being considered and we will report to shareholders when the process is concluded.
We have the opportunity of putting past issues behind us and building on the core IP within the business. As part of this "fresh start", I am delighted to welcome Stockdale Securities as our new Nominated Adviser and broker and look forward to working with them to help AorTech reach its true potential.
Bill Brown, Chairman 11 December 2017
- says it all
This is just the beginning of the new era
True rerate with top notch BoD. Things are just starting, unreal how undervalued this company is. 6 months with the right newsflow could see this ten bag. IMO
I am impressed with William Brown.
I believe a lot of effort and networking has gone into
the announcement, preceding the fundraising.
Much has changed over the years and I would not to
sure that this is a spike.
Dud management and litigation is I believe in the
past as ar as Aerotech are concerned.
These guys have been around for donkeys years. Made a shed load on them many many tears ago. problem is they have never delivered, so watch the spike, thats all I will say
400p broker target says it all really.
Ca.20mill mcap my first target.
Yeah, with the Patent for USA announced I can see this going bananas.
Can see this £1 next week no probs. Stateside buying imo, I know its a cliche but with manufacturing over their why not.
They sure are...corporate client buying hard.
Brokers buying at mid ?
I think someone is loading up quite heavily at this price, and who can blame them?
I can see interest really picking up here over the coming weeks, especially on the previous news. We should be looking at a minimum 20Million+ MCAP on the news we have seen, but further news could very well propel this a lot higher. IMO DYOR etc.
7 mn mcap is a complete joke tbh, this will re rate
60p will look a steal very soon.....
Thank you, glad I got it under 60p tbh
Come on give me a 1k top up please.
Solid plan in place - As mentioned on 21st May
the Company intends to enter into a development and manufacturing agreement with RUA Medical, a medical textiles manufacturer, and a development contract with Vascular Flow Technologies, a medical device development company. If successfully developed and approved by the relevant regulatory authorities, the Company proposes to employ what the Directors believe to be a lean sales and marketing strategy for its products, a distribution model to provide access to hospital markets and OEM sales of devices to other medical device companies.
19th June - Development Agreement signed with Vascular Flow Technologies Limited ("VFT")
28th June - Development and Supply Agreement with RUA Medical
Bonus of 26th June - Bill Brown, Chairman of AorTech said: "We are delighted that this US Patent has been issued extending further AorTech's world class portfolio of biostable polymers for medical device use."
So the next news includes a lean sales and marketing strategy for its products, a distribution model to provide access to hospital markets and OEM sales of devices to other medical device companies.
With the boarding of : -
John Ely (NED - Heart Valve Expert)
Geoffrey Berg (NED - Cardiovascular Expert)
David Richmond (NED - Product Development Expert)
Craig Dunlop & team at VFT (Consultant - Valve Engineering)
Edwin Lindsay at Compliance Solutions (Regulatory Affairs)
What's not to like?
Looking good.
Nicola likes it:
https://www.voxmarkets.co.uk/blogs/nic-charts-aortech-aor-arc-minerals-arcm-jersey-oil-gas-jog-live-company-group-lvcg-tlou-energy-tlou/
With only 15mill shares in circ I tend to agree with you. Is bouncing nicely off 50p
I suspect most will be regretting selling a week from now.
Understandable but short sighted imho
Patent tick, supply tick now just the contracts to come. Took a couple more in anticipation